No Data
No Data
Here's Why We're Not Too Worried About Syndax Pharmaceuticals' (NASDAQ:SNDX) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, although software-as-a-service business Salesforce.com
Syndax Pharmaceuticals(SNDX.US) Officer Buys US$25,037.25 in Common Stock
$Syndax Pharmaceuticals(SNDX.US)$ Officer Goldan Keith A. purchased 1,250 shares of common stock on Jun 14, 2024 at an average price of $20.0298 for a total value of $25,037.25.Source: Announcement Wh
Express News | Syndax Pharmaceuticals Inc: 52% Crc (14 of 27 Pts) Observed in Augment-102 Trial
Express News | Syndax Pharmaceuticals Inc: 96% Crc (23 of 24 Pts) Observed in Beat Aml Trial
Express News | Syndax Pharmaceuticals Inc: Plans to Initiate a Pivotal Trial With This Combination in Front-Line Newly Diagnosed Patients by Year-End 2024
Express News | Syndax Presents Updated Positive Data From Beat Aml and Augment-102 Phase 1/2 Combination Trials of Revumenib in Patients With Acute Leukemias at Eha 2024 Congress